Open AccessEarly Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series
Author(s) -
Petar Ugurov,
Dijana Popevski,
Tanja Gramosli,
Dashurie Neziri,
Dragica Vuckova,
Marko Gjorgon,
Emil Stoicovski,
Sanja Marinković,
Lidija Veljanovska-Kiridjievska,
Katerina Ignevska,
Sanja Mehandziska,
Elena Ambarkova,
Zan Mitrev,
Rodney Alexander Rosalia
Publication year - 2022
Publication title -
brazilian journal of cardiovascular surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.324
H-Index - 26
eISSN - 1678-9741
pISSN - 0102-7638
DOI - 10.21470/1678-9741-2020-0403
Subject(s) - medicine , ards , extracorporeal , fibrinogen , interquartile range , intensive care unit , hemofiltration , coagulopathy , procalcitonin , gastroenterology , systemic inflammation , sepsis , lung , inflammation , hemodialysis
Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS). We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support.